# US 2015/0105458 A1 · Line leaf inula flower lactone a and methods for preparing and using the same for treating multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105458 A1
- Document ID: US20150105458A1
- Status: Published application
- Kind: A1
- Application number: 14/576,164
- Filed: 2014-12-18
- Published: 2015-04-16
- Earliest claimed: 2012-06-21
- Assignees: Shanxi Zhendong Pilot Biological Science and Technology Co., Ltd.
- Applicants: Shanxi Zhendong Pilot Biological Science and Technology Co., Ltd.
- Inventors: Weidong ZHANG; Lei SHAN; Juan SU; Huizi JIN; Huiliang LI; Yunheng SHEN; Xike XU; Runhui LIU
- Web page: https://patentgrep.com/patent/US20150105458A1

## CPC

- C07D 307/93: condensed with a ring other than six-membered
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/365: Lactones
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/02: Immunomodulators
- A61K 2236/39: Complex extraction schemes, e.g. fractionation or repeated extraction steps
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

## Claims

### Claim 1

A pharmaceutical composition for treating multiple sclerosis, comprising an isolated and purified line leaf inula flower lactone A having a structure of

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier,
wherein the line leaf inula flower lactone A is a sole active ingredient in the composition.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is in a form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.

### Claim 4 (depends on 1)

A method for treating multiple sclerosis according to claim 1, comprising
administering a therapeutically effective amount of the pharmaceutical composition of claim 1 in a subject in need of treatment for multiple sclerosis.

### Claim 5 (depends on 4)

The method for treating multiple sclerosis according to claim 4, wherein the pharmaceutical composition is administered by intraperitoneal injection or intragastric administration.
